Patent rule irks bio firms
Lots of news out today. As always, I’ll try to pull out the stuff that’s less well covered by the mainstream press. Here’s a very big story developing from the USPTO on a proposed rule that would limit patent follow-on applications to one and claim number to 10. Wow. This would be a huge change of practice to biotech and pharma if implemented as proposed. Read the attached story and watch for the public outcry from industry with a move to the courts to prevent the rule implementation as proposed if necessary.
